Key result
Olaratumab plus doxorubicin improves overall survival versus doxorubicin alone in metastatic soft tissue sarcoma.
Why the study?
The outcome of patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options and no overall survival difference between combination anthracycline schedules and single-agent doxorubicin.
Does olaratumab combined with doxorubicin improve overall survival in patients with unresectable or metastatic soft tissue sarcoma?
Does olaratumab combined with doxorubicin improve overall survival in patients with unresectable or metastatic soft tissue sarcoma?
Olaratumab combined with doxorubicin provides a significant overall survival benefit in adult patients with anthracycline-naïve unresectable soft tissue sarcoma.
Answers are grounded in this paper and cite their sources.
Suggests potential OS benefit with olaratumab plus doxorubicin in STS; leaves open confirmation in Phase III.
The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-α (PDGFRα)-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naïve unresectable STS. In this review, we discuss the potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.
No takes yet. Share an insight, caveat, or question.
Pender et al. (2017) conducted a review in unresectable or metastatic soft tissue sarcoma (STS). Olaratumab was evaluated. Olaratumab combined with doxorubicin demonstrated a significant improvement in median overall survival compared to doxorubicin alone in patients with unresectable or metastatic soft tissue sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: